KIT and neoplasm: In 1998, Kindblom et al.[2] and Hirota et al.[3] independently determined that these neoplasms are significantly immunoreactive for CD117, a polyclonal antibody recognizing the type III tyrosine kinase KIT, which is encoded by the proto-oncogene c-kit.